Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of Anvirzel
(Nerium Oleander) that can be given to lung cancer patients receiving standard therapy with
carboplatin and docetaxel. Researchers also want to learn what effect Nerium Oleander may
have in combination with carboplatin and docetaxel.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) Nerium Biotechnology